| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 5,774 | 3,613 | ||
| General and administrative | 2,020 | 2,982 | ||
| Operating loss | -7,794 | -6,595 | ||
| Finance income | 332 | 261 | ||
| Net loss | -7,462 | -6,334 | ||
| Effect of warrant modification | 2,429 | - | ||
| Total net loss attributable to common shareholders | -9,891 | - | ||
| Basic weighted average number of shares outstanding | 22,719,057 | 21,366,268 | ||
| Earnings per share, basic | -0.44 | -0.3 | ||
| Earnings per share, diluted | -0.44 | -0.3 | ||
| Weighted average number of shares outstanding, diluted | 22,719,057 | 21,366,268 | ||
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT)